Lipid metabolism, Insulin signaling, and COX-2 pathways

The term Lipid metabolism, Insulin signaling, and COX-2 pathways refers to a complex network of interconnected biological processes rather than a single molecular target. Lipid metabolism encompasses the synthesis and breakdown of fats, which is tightly regulated by insulin signaling to maintain energy homeostasis (StatPearls). Cyclooxygenase-2 (COX-2), also known as Prostaglandin-endoperoxide synthase 2, is an inducible enzyme that converts arachidonic acid into pro-inflammatory prostaglandins (NCBI Gene). Chronic inflammation mediated by COX-2 is known to contribute to insulin resistance, creating a link between inflammatory signaling and metabolic disorders like Type 2 diabetes and obesity (PubMed). Pharmacological intervention typically targets specific components within these pathways, such as using statins for lipid control, sensitizers for insulin signaling, or NSAIDs for COX-2 inhibition (PubChem). Understanding the crosstalk between these pathways is crucial for developing multi-target therapies for metabolic syndrome and associated cardiovascular risks. Dysregulation in these pathways often leads to the accumulation of lipid metabolites that interfere with the insulin receptor substrate (IRS) signaling cascade. Consequently, therapeutic strategies often aim to balance lipid levels and reduce inflammation to restore normal insulin sensitivity.

Other names

Metabolic and inflammatory signaling networksInsulin-Lipid-COX2 axisMetabolic-inflammatory crosstalk

Drugs interacting with these pathways function through diverse mechanisms including the activation of the insulin receptor tyrosine kinase, inhibition of HMG-CoA reductase to lower cholesterol, and selective or non-selective inhibition of the cyclooxygenase-2 enzyme to reduce prostaglandin synthesis.